Novo Nordisk A/S, Non-Clinical & Clinical Assay Sciences, Global Discovery & Development Sciences, Global Drug Discovery, Maløv, DK-2760, Denmark.
Bayer AG, DMPK Project Management, Research & Development, Pharmaceuticals, Berlin, 13342, Germany.
Bioanalysis. 2021 Dec;13(23):1723-1729. doi: 10.4155/bio-2021-0218. Epub 2021 Oct 28.
Polymerase chain reaction (PCR) is widely used in various fields of laboratory testing, ranging from forensic, molecular biology, medical and diagnostic applications to a wide array of basic research purposes. COVID-19 infection testing has brought the three-letter PCR abbreviation into the vocabulary of billions of people, making it likely the most well-known laboratory test worldwide. With new modalities and translational medicine gaining importance in pharmaceutical research and development, PCR or more specifically, quantitative PCR (qPCR) is now becoming a standard tool in the (regulated) bioanalytical laboratory, driving the bioanalytical community to define best practices for method development, characterization and validation. In absence of specific guidance from health authorities, qPCR may be vulnerable to scope creep from pharmacokinetics (PK) assay validation as defined in bioanalytical method validation guidance/guidelines. In this manuscript, the European Bioanalysis Forum builds a rationale for applying context of use principles when defining requirements for qPCR assay performance and validation criteria.
聚合酶链式反应(PCR)广泛应用于实验室检测的各个领域,包括法医、分子生物学、医学和诊断应用以及广泛的基础研究目的。COVID-19 感染检测使 PCR 这三个字母的缩写进入了数十亿人的词汇,使其成为全球最知名的实验室检测方法。随着新的模式和转化医学在药物研发中的重要性日益增加,PCR 或更具体地说,定量 PCR(qPCR)现在成为(监管)生物分析实验室的标准工具,推动生物分析界为方法开发、特征描述和验证定义最佳实践。由于缺乏来自卫生当局的具体指导,qPCR 可能容易受到来自药代动力学(PK)分析验证的范围扩大的影响,PK 分析验证是生物分析方法验证指南/准则中定义的。在本文中,欧洲生物分析论坛为在定义 qPCR 分析性能要求和验证标准时应用使用场景原则建立了基本原理。